The marketing applications for two Category 1 therapeutic biologics developed by Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a core enterprise of Sino Biopharmaceutical Limited (HKG: 1177), were accepted by China’s National Medical Products Administration (NMPA). The filings cover TQB2102, a HER dual‑antibody ADC for HER2‑low breast cancer, and TQH2722, a fully human anti‑IL‑4Rα monoclonal antibody for moderate‑to‑severe atopic dermatitis (AD) — a dual‑asset advance spanning oncology and immunology.
Regulatory Milestone
| Item | TQB2102 | TQH2722 |
|---|---|---|
| Agency | NMPA (China) | NMPA (China) |
| Application Type | Marketing application – Category 1 therapeutic biologic (accepted) | Marketing application – Category 1 therapeutic biologic (accepted) |
| Modality | HER dual‑antibody antibody‑drug conjugate (ADC) | Fully human monoclonal antibody (anti‑IL‑4Rα) |
| Proposed Indication | Adult patients with unresectable or metastatic HER2‑low (IHC 1+ or IHC 2+/ISH‑) breast cancer, chemotherapy‑naïve in the recurrent/metastatic setting | Adults with moderate‑to‑severe atopic dermatitis inadequately controlled with or unsuitable for topical therapies |
| Pivotal Trial | Phase III study TQB2102‑III‑01 | Phase III trial TQH2722‑III‑01 |
| Announcement Date | 16 September 2026 | 16 September 2026 |
TQB2102 – Drug Profile & Clinical Evidence
- Molecule: TQB2102, a HER dual‑antibody ADC independently developed by CTTQ, leveraging bispecific HER‑directed targeting for payload delivery.
- Target Population: HER2‑low breast cancer (IHC 1+ or IHC 2+/ISH‑) — a subgroup historically treated as HER2‑negative and underserved by conventional anti‑HER2 therapy.
- Line of Therapy: Patients who have not received prior chemotherapy in the recurrent or metastatic setting — positioning TQB2102 for early use in the advanced‑disease treatment sequence.
- Phase III Trial (TQB2102‑III‑01): Enrolled 543 patients with HER2‑low breast cancer.
- Primary Endpoint Results: Compared with investigator‑selected chemotherapy, TQB2102 significantly reduced the risk of disease progression or death, with progression‑free survival (PFS) achieving a statistically significant and clinically meaningful improvement.
TQH2722 – Drug Profile & Clinical Evidence
- Molecule: TQH2722 injection, a fully human monoclonal antibody targeting interleukin‑4 receptor alpha (IL‑4Rα).
- Mechanism: By specifically binding to IL‑4Rα, it simultaneously inhibits signaling pathways mediated by both IL‑4 and IL‑13, blocking the type 2 inflammatory pathway upstream — the central driver of atopic dermatitis pathology.
- Target Population: Adults with moderate‑to‑severe AD whose disease is inadequately controlled with or unsuitable for topical therapies.
- Phase III Trial (TQH2722‑III‑01): Enrolled 500 patients.
- Co‑Primary Endpoints: Both the Week 16 EASI‑75 response rate and IGA 0/1 response rate were met; multiple secondary endpoints also achieved prespecified targets, with all efficacy measures demonstrating consistent and significant treatment benefits.
Market Impact & Outlook
- Dual‑Franchise Momentum: Simultaneous acceptance of two Category 1 marketing applications underscores CTTQ’s innovation pipeline depth and its parent Sino Biopharmaceutical’s diversification across oncology and immunology.
- HER2‑Low Opportunity: With the HER2‑low paradigm reshaping breast cancer classification, TQB2102 targets a large, newly defined patient segment — and its chemotherapy‑naïve positioning could move ADC use earlier in the treatment algorithm.
- Immunology Competition: TQH2722 enters the rapidly expanding biologic AD market, where IL‑4Rα blockade is validated as a cornerstone mechanism; consistent Phase III efficacy across co‑primary and secondary endpoints supports a competitive filing.
- Regulatory Trajectory: NMPA acceptance initiates formal technical review; approval decisions for both products remain pending completion of the review process.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory review timelines, approval outcomes, and commercial expectations for TQB2102 and TQH2722. Application acceptance does not guarantee approval. Actual results may differ due to risks including CDE review findings, manufacturing and quality requirements, safety surveillance, and competitive dynamics in the breast cancer ADC and atopic dermatitis biologic markets.-Fineline Info & Tech
